CSIMarket
 
Fennec Pharmaceuticals Inc   (FENCF)
Other Ticker:  
 
 
Price: $0.0000 $0.00 %
Day's High: 0.00 Week Perf:
Day's Low: $ 0.00 30 Day Perf:
Volume (M): 0 52 Wk High: $ 0.00
Volume (M$): $ 0 52 Wk Avg: $0.00
Open: $0.00 52 Wk Low: $0.00



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) 31
 Employees -
 Revenues (TTM) (Millions $) 35
 Net Income (TTM) (Millions $) 6
 Cash Flow (TTM) (Millions $) 33
 Capital Exp. (TTM) (Millions $) 0

Fennec Pharmaceuticals Inc


   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Fennec Pharmaceuticals Inc

2. Fennec Pharmaceuticals Inc Achieves Remarkable Revenue Growth and Positive Income in Q1 2024 Financial Results



Fennec Pharmaceuticals Inc, a well-known player in the pharmaceutical industry, has reported astonishing revenue growth of 1413.238% year on year, amounting to $25.38 million in its fiscal time-frame ending March 31, 2024. This remarkable achievement has propelled the company's income to turn positive at $0.41 per share, indicating a significant improvement from the previous reporting season.
Positive Income Growth
In the previous reporting season, Fennec Pharmaceuticals Inc reported a zero income per share, which has now soared to $0.41, reflecting the successful measures undertaken by the company to enhance its financial health. Furthermore, the income has risen from $0.00 million to $12.837 million during the January to March 31, 2024 financial time-frame. This substantial earnings growth signals the company's ability to convert its increasing revenue into profits.

Fennec Pharmaceuticals Inc

Fennec Pharma Delivers Impressive Revenue of $6.515 Million, Making Waves in the Pharmaceutical Industry

Fennec Pharmaceuticals Inc, a pharmaceutical company, recently released its financial report for the July to September 30, 2023 period. In this span, the company achieved a revenue of $6.515 million, which is a significant increase compared to the same reporting season in the previous year. Fennec Pharmaceuticals Inc had previously reported a net deficit of $-8.089 million during this period last year; however, it managed to reduce this deficit to $-1.867 million in the current year.
These positive financial results indicate a strong performance for Fennec Pharmaceuticals Inc in the July to September 30, 2023 period. The company's efforts to increase revenue and reduce losses seem to be paying off. It is noteworthy that the revenue for this period has substantially improved, indicating that the company's products or services have gained better market traction. This growth in revenue may be attributed to various factors such as increased sales, new marketing strategies, improved product quality, or expansion into new markets.

Fennec Pharmaceuticals Inc

Fennec Pharmaceuticals Inc Announces Surprising Revenue of $3.325 Million, But Why Did Profits Plummet?

Fennec Pharmaceuticals Inc, a renowned biopharmaceutical company, has recently released its financial results for the fiscal second quarter of 2023. The company has garnered a revenue of $3.325 million during this period. However, the company's net shortfall for this quarter stood at $-5.444 million, which is comparatively larger than the shortfall of $-5.072 million recorded during the same period the previous year.
These figures highlight Fennec Pharmaceuticals Inc's current financial performance, indicating a decline in profitability. It is imperative to evaluate various factors that may have contributed to this negative outcome and understand the potential implications on the company's future standing.

Fennec Pharmaceuticals Inc

Fennec Pharmaceuticals Inc Boosts Revenue to Impressive $1.677 Million, According to the Recent Report

In a recent report released by Fennec Pharmaceuticals Inc, the company has reported a cumulative net loss of $-26 million during the 12 months leading up to the first quarter of 2023. This has resulted in a negative return on investment (ROI) of -131.32%. This places FENCF at a disadvantage when compared to other companies in the healthcare sector, with 538 other companies reporting a higher ROI.
However, there is some good news for Fennec Pharmaceuticals Inc, as their return on investment ranking has progressed to 2977 in the Mar 31 2023 quarter, up from 4862 in the fourth quarter of 2022. While their progress is not yet significant enough to compete with other healthcare sector companies, it is still a step in the right direction.






 

Fennec Pharmaceuticals Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com